The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View all content recommended for you
Does adding inotuzumab ozogamicin to frontline therapy improve survival outcomes for adults with B-ALL?
Featured:
Nicholas J. ShortDuring the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the ALL Hub was pleased to speak to Nicholas Short, MD Anderson Cancer Center, Houston, US. We asked, Does adding inotuzumab ozogamicin to frontline therapy improve survival outcomes for adults with B-ALL?
Does adding inotuzumab ozogamicin to frontline therapy improve survival outcomes for adults with B-ALL?
Short begins by discussing the recent improvements in overall survival for patients with B-ALL following the introduction of inotuzumab ozogamicin, particularly in the relapsed/refractory setting. Short then outlines several combination treatments that include this anti-CD22 antibody-drug conjugate and their resulting long-term survival rates. The difference in response between older and younger adults is also discussed. Short concludes by looking to the future of combination and sequential therapies within standard treatment which could further improve outcomes and reduce the need of transplant in patients with ALL.
Your opinion matters
On average, how many patients with T-cell acute lymphoblastic leukemia do you see in a year?